10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-ENTPD1 / CD39 Reference Antibody (TTX-030)

Recombinant Antibody
Catalog # APR10301

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P49961
Reactivity	Human
Clonality	Monoclonal
Isotype	Human IgG4
Calculated MW	57965


Additional Information

Target/Specificity	ENTPD1 / CD39
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Name	ENTPD1 (HGNC:3363)
Function	Catalyzes the hydrolysis of nucleoside triphosphates (NTPs) and diphosphates (NDPs) (Probable) (PubMed:8529670, PubMed:8626624, PubMed:8955160, PubMed:8996251). The enzyme sequentially removes phosphate groups in two successive steps, converting NTPs to nucleoside monophosphates (NMPs) via NDP intermediates (Probable) (PubMed:8529670, PubMed:8626624, PubMed:8955160, PubMed:8996251). This activity contributes to the regulation of extracellular levels of nucleotides (Probable) (PubMed:8529670, PubMed:8626624, PubMed:8955160, PubMed:8996251). By hydrolyzing proinflammatory ATP and platelet-activating ADP to AMP, it blocks platelet aggregation and supports blood flow (PubMed:8955160, PubMed:8996251).
Cellular Location	Membrane; Multi-pass membrane protein. Membrane, caveola
Tissue Location	Expressed primarily on activated lymphoid cells (PubMed:7930580). Also expressed in endothelial tissues (PubMed:8955160). Highly expressed in placenta, lung, skeletal muscle, kidney (PubMed:8955160).


Images



Anti- Human CD39(TTX-030) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti- Human CD39(TTX-030) is 99.83%, determined by SEC-HPLC.



Anti- Human CD39(TTX-030) inhibited the tumor growth of MOLP-8 on NCG mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 99.3% at 20 mpk at D25.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.